Calcium signaling affects migration and proliferation differently in individual cancer cells due to nifedipine treatment.
Antineoplastic Agents, Immunological
/ pharmacology
Apoptosis
/ drug effects
Breast Neoplasms
/ genetics
Calcium Channel Blockers
/ pharmacology
Calcium Signaling
/ drug effects
Cell Line, Tumor
Cell Movement
/ drug effects
Cell Proliferation
/ drug effects
Colorectal Neoplasms
/ genetics
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Inositol 1,4,5-Trisphosphate Receptors
/ genetics
Nifedipine
/ pharmacology
Ovarian Neoplasms
/ genetics
RNA Interference
Receptor, ErbB-2
/ genetics
Sodium-Calcium Exchanger
/ genetics
Trastuzumab
/ pharmacology
Triple Negative Breast Neoplasms
/ genetics
Apoptosis
Breast cancer
Inositol 1,4,5-trisphosphate receptor
Migration
Sodium calcium exchanger 1
Journal
Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
12
09
2019
accepted:
05
11
2019
pubmed:
11
11
2019
medline:
28
7
2020
entrez:
11
11
2019
Statut:
ppublish
Résumé
Several papers have reported that calcium channel blocking drugs were associated with increased breast cancer risk and worsened prognosis. One of the most common signs of breast tumors is the presence of small deposits of calcium, known as microcalcifications. Therefore, we studied the effect of dihydropyridine nifedipine on selected calcium transport systems in MDA-MB-231 cells, originating from triple negative breast tumor and JIMT1 cells that represent a model of HER2-positive breast cancer, which possesses amplification of HER2 receptor, but cells do not response to HER2 inhibition treatment with trastuzumab. Also, we compared the effect of nifedipine on colorectal DLD1 and ovarian A2780 cancer cells. Both, inositol 1,4,5-trisphosphate receptor type 1 (IP
Identifiants
pubmed: 31706846
pii: S0006-2952(19)30394-6
doi: 10.1016/j.bcp.2019.113695
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Calcium Channel Blockers
0
Inositol 1,4,5-Trisphosphate Receptors
0
Sodium-Calcium Exchanger
0
sodium-calcium exchanger 1
0
Receptor, ErbB-2
EC 2.7.10.1
Nifedipine
I9ZF7L6G2L
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113695Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.